Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: A systematic review

JAMA

Volumn 298, Issue 6, 2007, Pages 655-669

  Bosch, Xavier ^a,c   Guilabert, Antonio ^a   Espinosa, Gerard ^a   Mirapeix, Eduard ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTHRITIS; BONE MARROW SUPPRESSION; CANCER RISK; CHURG STRAUSS SYNDROME; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTITIS; CYTOPENIA; DATA SYNTHESIS; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE INFERTILITY; HERPES ZOSTER; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; KIDNEY DISEASE; LEUKOPENIA; LOW DRUG DOSE; LUNG EDEMA; MALIGNANT NEOPLASTIC DISEASE; MICROSCOPIC POLYANGIITIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS; IMMUNOLOGY; PATHOPHYSIOLOGY; REMISSION; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PLASMA EXCHANGE; REMISSION INDUCTION; VASCULITIS;

EID: 34547799013     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.6.655     Document Type: Review

References (104)

1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet. 2006;368(9533):404-418.
2. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117(1):39-50.
3. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996;39(1):87-92.
4. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol. 2005;64(6):480-484.
5. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958;2(5091):265-270.
6. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med. 1967;67(2):393-398.
7. Fauci AS, Wolff SM. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore). 1973;52(6):535-561.
8. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116(6):488-498.
9. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36-44.
10. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461-2469.
11. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol. 2006;18(1):25-32.
12. Flossmann O, Jones RB, Jayne DR, Luqmani RA. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis. 2006;65(7):841-844.
13. Goek ON, Stone JH. Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol. 2005;17(3):257-264.
14. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37(2):187-192.
15. Bosch X. Microscopic polyangiitis (microscopic polyarteritis) with late emergence of generalised Wegener's granulomatosis. Ann Rheum Dis. 1999;58(10):644-647.
16. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994;37(6):919-924.
17. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997;72(8):737-747.
18. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. Mayo Clin Proc. 1985;60(1):27-32.
19. DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? Arthritis Rheum. 1988;31(8):1068-1074.
20. Reinhold-Keller E, De Groot K, Rudert H, Nolle B, Heller M, Gross WL. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM. 1996;89(1):15-23.
21. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG; Dutch Co-Trimoxazole Wegener Study Group. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335(1):16-20.
22. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation. http://www.cebm.net/levels_of_evidence.asp. Accessed May 21, 2007.
23. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35(11):1322-1329.
24. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum. 1995;38(5):608-613.
25. Stone JH, Tun W, Hellman DB. Treatment of nonlife threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol. 1999;26(5):1134-1139.
26. de Groot K, Muhler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol. 1998;25(3):492-495.
27. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials. 2002;23(4):450-468.
28. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351-361.
29. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med. 2003;114(6):463-469.
30. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum. 2002;47(3):326-332.
31. Jayne D. What place for the new biologics in the treatment of necrotising vasculitides. Clin Exp Rheumatol. 2006;24(2)(suppl 41):S1-S5.
32. Sarraf P, Kay J, Friday RP, Reginato AM. Wegener's granulomatosis: is biologic therapy useful? Curr Rheumatol Rep. 2006;8(4):303-311.
33. Mahr A, Pagnoux C, Cohen C, et al. Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT). Kidney Blood Press Res. 2005;28:194.
34. Sanders JSF, Stassen PM, Kallenberg CGM, Stegeman CA. Azathioprine as compared to cyclophosphamide maintenance therapy for ANCA-associated vasculitis is associated with increased long-term relapse risk. Kidney Blood Press Res. 2005;28:195.
35. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 2004;51(2):269-273.
36. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol. 1999;10(9):1965-1971.
37. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum. 2004;51(2):278-283.
38. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract. 2006;102(3-4):c100-c107.
39. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford). 2004;43(3):315-320.
40. Metzler C, Wagner-Bastmeyer R, Gross WL, Reinhold-Keller E. Leflunomide versus methotrexate for maintenance of remission in Wegener's granulomatosis: Unexpected high relapse rate under oral methotrexate. Ann Rheum Dis. 2005;64(1)(suppl 3):85.
41. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 1999;42(12):2666-2673.
42. de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum. 1996;39(12):2052-2061.
43. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum. 2000;43(8):1836-1840.
44. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum. 2000;43(5):1021-1032.
45. Hoffman GS. "Wegener's granulomatosis": the path traveled since 1931. Medicine (Baltimore). 1994;73(6):325-329.
46. Brandwein S, Esdaile J, Danoff D, Tannenbaum H. Wegener's granulomatosis: clinical features and outcome in 13 patients. Arch Intern Med. 1983;143(3):476-479.
47. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum. 2000;43(9):2025-2033.
48. Dhaygude A, Griffith M, Cairns T, McLean A, Palmer A, Taube D. Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis. Nephron Clin Pract. 2004;97(4):c154-c159.
49. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76-85.
50. Lynch JP III, White E, Tazelaar H, Langford CA. Wegener's granulomatosis: evolving concepts in treatment. Semin Respir Crit Care Med. 2004;25(5):491-521.
51. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 1997;40(12):2187-2198.
52. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. Rheumatology (Oxford). 2001;40(5):492-498.
53. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477-484.
54. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol. 1998;37(6):659-664.
55. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med. 1990;89(4):403-410.
56. Falk RJ, Hogan S, Carey TS, Jennette JC; The Glomerular Disease Collaborative Network. . Clinical course of anti-neutrophil cytoplasmic autoantibodyassociated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113(9):656-663.
57. Boki KA, Dafni U, Karpouzas GA, Papasteriades C, Drosos AA, Moutsopoulos HM. Necrotizing vasculitis in Greece: clinical, immunological, and immunogenetic aspects: a study of 66 patients. Br J Rheumatol. 1997;36(10):1059-1066.
58. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant. 1991;6(8):531-535.
59. Lê Thi Huong D, Papo T, Piette JC, et al. Monthly intravenous pulse cyclophosphamide therapy in Wegener's granulomatosis. Clin Exp Rheumatol. 1996;14(1):9-16.
60. Drosos AA, Sakkas LI, Goussia A, Siamopoulos KC, Moutsopoulos HM. Pulse cyclophosphamide therapy in Wegener's granulomatosis: a pilot study. J Intern Med. 1992;232(3):279-282.
61. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis. 1997;56(8):481-487.
62. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49(1):93-100.
63. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997;90(6):401-409.
64. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum. 1998;41(10):1835-1844.
65. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant. 2001;16(10):2018-2027.
66. De Groot K, Jayne CRW, Tesar V. Savage COS for EUVAS. Randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis. Kidney Blood Press Res. 2005;28:195.
67. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15(3):717-721.
68. Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology, and prognosis. Q J Med. 1985;56(220):467-483.
69. Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993;86(12):779-789.
70. Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM. 1995;88(2):127-133.
71. De'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and antineutrophil cytoplasmic antibody concentration in longterm management of systemic vasculitis. Am J Kidney Dis. 1995;25(3):380-389.
72. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9(5):842-852.
73. Sanders JS, Slot MC, Stegeman CA. Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(21):2072-2073.
74. White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. Drugs. 2006;66(9):1209-1228.
75. Booth AD, Almond MK, Burns A, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41(4):776-784.
76. Frascà GM, Zoumparidis NG, Borgnino LC, Neri L, Vangelista A, Bonomini V. Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodies. Int J Artif Organs. 1992;15(3):181-184.
77. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Jorstad S. Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange. Blood Purif. 2002;20(2):167-173.
78. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149-1153.
79. Frascà GM, Soverini ML, Falaschini A, Tampieri E, Vangelista A, Stefoni S. Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther Apher Dial. 2003;7(6):540-546.
80. Kokolina E, Alexopoulos E, Dimitriadis C, et al. Immunosuppressive therapy and clinical evolution in forty-nine patients with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Ann NY Acad Sci. 2005;1051:597-605.
81. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757-763.
82. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93(7):433-439.
83. Richter C, Schnabel A, Csernok E, De Groot K, Reinhold-Keller E, Gross WL. Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995;101(1):2-7.
84. Jayne DR, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol. 1993;336:469-472.
85. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis. 2007;66(6):798-802.
86. Birck R, Warnatz K, Lorenz HM, et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month openlabel trial to evaluate safety and efficacy. J Am Soc Nephrol. 2003;14(2):440-447.
87. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65(4):1440-1448.
88. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(1):262-268.
89. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173(2):180-187.
90. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum. 2005;52(1):1-5.
91. Guillevin L, Jarrousse B, Lok C, et al; The Cooperative Study Group for Polyarteritis Nodosa. Long-term followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange: a prospective randomized trial of 71 patients. J Rheumatol. 1991;18(4):567-574.
92. Guillevin L, Fain O, Lhote F, et al. Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective, randomized trial in 78 patients. Arthritis Rheum. 1992;35(2):208-215.
93. Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis: a prospective, randomized trial in sixty-two patients. Arthritis Rheum. 1995;38(11):1638-1645.
94. Gayraud M, Guillevin L, Cohen P, et al; French Cooperative Study Group for Vasculitides. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol. 1997;36(12):1290-1297.
95. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 2001;44(3):666-675.
96. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore). 1996;75(1):17-28.
97. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore). 2005;84(5):323-330.
98. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78(1):26-37.
99. Pagnoux C, Cohen P, Mahr A, et al. Treatment of Churg-Strauss syndrome with poor prognostic factors. A prospective, randomized, multicenter trial comparing corticosteroids and 6 vs 12 cyclophosphamide pulses. Arthritis Rheum. 2003;49:S661.
100. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005;64(suppl 4):iv31-iv36.
101. Rosenstiel P, Agnholt J, Kelsen J, et al. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease. Gut. 2005;54(2):314-315.
102. Sieper J, Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. Semin Arthritis Rheum. 2005;34(5)(suppl 1):23-27.
103. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on ANCA-associated vasculitis. Ann Rheum Dis. 2007;66(5):605-617.
104. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.